BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14577451)

  • 21. Patent immorality?
    Bloche MG; Jungman ER
    Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
    [No Abstract]   [Full Text] [Related]  

  • 22. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patents or patients? Global access to pharmaceuticals and social justice.
    de Wildt G; Khoon CC
    Med Confl Surviv; 2008; 24 Suppl 1():S52-61. PubMed ID: 18771195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patents and the obligation to protect health: examining the significance of human rights considerations in the protection of pharmaceutical patents.
    Owoeye OA
    J Law Med; 2014 Jun; 21(4):900-19. PubMed ID: 25087369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
    Baker BK
    PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
    Guennif S
    Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
    Curti AM
    Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
    [No Abstract]   [Full Text] [Related]  

  • 31. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
    Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intellectual property, patents and access to medication in developing countries].
    Esteve E
    Gac Sanit; 2001; 15(6):546-9. PubMed ID: 11858792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Out-licensing: a practical approach for improvement of access to medicines in poor countries.
    Friedman MA; den Besten H; Attaran A
    Lancet; 2003 Jan; 361(9354):341-4. PubMed ID: 12559883
    [No Abstract]   [Full Text] [Related]  

  • 37. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
    Faunce TS; Tomossy GF
    Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

  • 40. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.